Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vericel ( (VCEL) ) has shared an announcement.
On January 13, 2026, Vericel reported preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025, expecting total 2025 net revenue of about $276 million, including $239.5 million from MACI and $36.5 million from its burn care portfolio. The company anticipates a 74% gross margin, a 26% adjusted EBITDA margin, GAAP net income profitability for a second consecutive year, and a cash and investments balance of $200 million with no debt, driven by 23% fourth-quarter revenue growth and at least 20% annual MACI revenue growth for the third straight year. Operationally, Vericel reported record quarterly volumes in MACI implants and biopsies, a completed MACI sales force expansion, more than 900 MACI Arthro-trained surgeons by year-end 2025, the initiation of the MACI Ankle MASCOT clinical study, and continued progress toward starting MACI commercial manufacturing at a new facility in 2026, underscoring its strengthening position in cell-based sports medicine therapies and capacity expansion to support future demand. These results remain subject to completion of internal controls, review and audit procedures and may change once final financial statements are issued.
The most recent analyst rating on (VCEL) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Vericel stock, see the VCEL Stock Forecast page.
Spark’s Take on VCEL Stock
According to Spark, TipRanks’ AI Analyst, VCEL is a Outperform.
Vericel’s overall stock score is driven by strong financial performance and positive technical indicators, indicating a solid growth trajectory. The earnings call further supports this with record revenue and strategic initiatives for future growth. However, the high P/E ratio suggests the stock may be overvalued, which is a risk factor to consider.
To see Spark’s full report on VCEL stock, click here.
More about Vericel
Vericel Corporation is a Cambridge, Massachusetts-based biopharmaceutical company specializing in advanced therapies for the sports medicine and severe burn care markets. Its U.S. portfolio includes MACI, an autologous cellularized scaffold for repairing full-thickness cartilage defects of the knee, Epicel, a permanent skin replacement for patients with extensive deep dermal or full-thickness burns, and NexoBrid, a licensed enzymatic debridement therapy for eschar removal in adults and pediatric burn patients.
Average Trading Volume: 632,568
Technical Sentiment Signal: Buy
Current Market Cap: $1.95B
See more data about VCEL stock on TipRanks’ Stock Analysis page.